SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.73    0.184 (33.70%)
Bid:
0.602
Ask:
0.73
Spread: 0.128 (21.262%)
Market Cap: £4.24m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Block Listing Update

24 Nov 2017 13:08

RNS Number : 4913X
Futura Medical PLC
24 November 2017
 

24 November 2017

 

 

 

Futura Medical plc

("Futura" or "the Company")

 

Block Listing Update

 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology makes the following update on its block listing, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over ordinary shares of 0.2 pence each.

The table below provides further detail.

 

Name of company:

Futura Medical plc

Name of scheme:

Unapproved Share Option Scheme ("USOS")EMI Share Option Scheme ("EMI")

Period of return:

From:

25 May 2017

To:

24 November 2017

 

Number and class of securities not issued under the scheme(s) at start of period

USOS:

2,446,110

EMI:

3,021,390

Total:

5,467,500

 

Number of securities issued under the scheme(s) during the period

 

Number of securities lapsed under the scheme(s) during the period

USOS:

-

EMI:

 

USOS:

EMI:

 

-

 

50,000

350,000

 

Balance under the scheme(s) of securities not yet issued at the end of the period

USOS:

2,396,110

EMI:

2,671,390

Total:

5,067,500

 

Number and class of securities originally admitted and the date of admission

USOS:

814,424 on 25 May 2011, 1,202,280 on 8 October 2013, 1,466,208 on 25 May 2017

USOS Total:

3,482,912

EMI:

1,520,576 on 25 May 2011, 1,467,720 on 8 October 2013

1,893,792 on 25 May 2017

EMI Total:

4,882,088

Total:

8,365,000

 

Name of contact:

Derek Martin, Chief Financial Officer

Telephone number of contact:

+44 (0) 1483 685 670

 

 

For further information please contact:

 

Futura Medical plc

 

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

Email to: james.barder@futuramedical.com

www.futuramedical.com

 

N+1 Singer (Nominated Adviser and Broker)

 

Aubrey Powell / Liz Yong

Corporate Finance

 

Tel:+44 (0) 20 7496 3000

For media enquiries please contact:

 

Buchanan

 

Mark Court / Sophie Cowles / Stephanie Watson

Tel: +44 (0) 20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPGGWUGUPMGWC
Date   Source Headline
30th Mar 20212:18 pmRNSNotice of Results
25th Mar 20214:41 pmRNSSecond Price Monitoring Extn
25th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 202111:05 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Mar 20212:05 pmRNSSecond Price Monitoring Extn
23rd Mar 20212:01 pmRNSPrice Monitoring Extension
23rd Mar 20219:05 amRNSSecond Price Monitoring Extn
23rd Mar 20219:00 amRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSUS FDA Agreement for Confirmatory Clinical study
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
19th Mar 202111:06 amRNSSecond Price Monitoring Extn
19th Mar 202111:00 amRNSPrice Monitoring Extension
19th Mar 20217:00 amRNSFutura Receives Recommendation for Approval
4th Mar 20212:05 pmRNSSecond Price Monitoring Extn
4th Mar 20212:00 pmRNSPrice Monitoring Extension
4th Mar 20219:06 amRNSSecond Price Monitoring Extn
4th Mar 20219:00 amRNSPrice Monitoring Extension
4th Mar 20217:00 amRNSFutura Announces Investment & Joint Collaboration
25th Feb 20212:06 pmRNSSecond Price Monitoring Extn
25th Feb 20212:01 pmRNSPrice Monitoring Extension
22nd Feb 20214:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20214:36 pmRNSPrice Monitoring Extension
22nd Feb 20212:05 pmRNSSecond Price Monitoring Extn
22nd Feb 20212:00 pmRNSPrice Monitoring Extension
18th Feb 202111:06 amRNSSecond Price Monitoring Extn
18th Feb 202111:00 amRNSPrice Monitoring Extension
15th Dec 20202:00 pmRNSPrice Monitoring Extension
15th Dec 20209:05 amRNSSecond Price Monitoring Extn
15th Dec 20209:00 amRNSPrice Monitoring Extension
8th Dec 20207:00 amRNSFutura provides US regulatory & commercial update
1st Dec 20207:00 amRNSBlock Listing Six Monthly Return
22nd Oct 20207:00 amRNSFutura provides regulatory and commercial update
21st Sep 20203:12 pmRNSDirector/PDMR Shareholding
16th Sep 20207:00 amRNSInterim Results for Six Months ended 30 June 2020
10th Sep 20204:41 pmRNSSecond Price Monitoring Extn
10th Sep 20204:35 pmRNSPrice Monitoring Extension
17th Aug 20207:00 amRNSNotice of Results
10th Aug 20207:00 amRNSFutura receives positive QMS Audit Opinion
4th Aug 20207:00 amRNSFutura update on CBD100 1st Stage Development Work
24th Jul 20204:40 pmRNSSecond Price Monitoring Extn
24th Jul 20204:35 pmRNSPrice Monitoring Extension
14th Jul 20207:00 amRNSFutura Medical provides EU & US regulatory update
10th Jul 20204:31 pmRNSBlock listing Interim Review - Replacement
24th Jun 20204:22 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.